Penserra Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Penserra Capital Management’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,267	Closed	-$15K	–	607
2017 Q1	$15K	Buy	8,267 +3,543	+75%	+$16K	﹤0.01%	416
2016 Q4	$24K	Buy	4,724 +460	+11%	+$2.42K	﹤0.01%	536
2016 Q3	$23K	Buy	4,264 +1,066	+33%	+$6.08K	﹤0.01%	472
2016 Q2	$18K	Sell	3,198 -346	-10%	-$1.82K	﹤0.01%	483
2016 Q1	$15	Buy	3,544 +1,181	+50%	+$4.86K	﹤0.01%	480
2015 Q4	$14K	Buy	+2,363	New	+$16K	﹤0.01%	472

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Penserra Capital Management's GNMX Position: Q2 2017 in Review

Penserra Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 8,267 shares — an estimated $15K sold.

Penserra Capital Management first reported a position in GNMX in Q4 2015 and held it in 6 quarters. The position peaked at $24K in Q4 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Penserra Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Penserra Capital Management sold 8,267 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $15K.
Penserra Capital Management first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 6 quarters.
Penserra Capital Management's Aevi Genomic Medicine Inc position peaked at $24K in Q4 2016.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Penserra Capital Management's 13F filing for Q2 2017, filed 7 Aug 2017.